Chronic liver disease, etiology,clinical features,diagnosis,treatment, according to Harrison

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have rich content on all the major sections. Let me now compile the comprehensive Harrison's-based answer on Chronic Liver Disease.

Chronic Liver Disease (Cirrhosis)

Harrison's Principles of Internal Medicine, 22nd Edition (2025)

Definition & Pathogenesis

Chronic liver disease leading to cirrhosis is defined by disruption of normal hepatic architecture with replacement of liver cells by regenerative nodules, the result of progressive fibrosis. Fibrosis can be centrilobular, pericellular, or periportal. Once regenerative nodules form, the condition is staged as:

Stage 3: Bridging fibrosis with nodularity
Stage 4: Cirrhosis (established)

Two key clinical phases:

Compensated cirrhosis - stable, often asymptomatic; HVPG 5-10 mmHg; can last >10 years
Decompensated cirrhosis - onset of ascites, variceal bleeding, or hepatic encephalopathy; median mortality <2 years after decompensation

Etiology

Harrison's classifies causes into the following groups (Table 355-1):

Category	Causes
Alcohol	Alcohol-associated cirrhosis (most common in USA)
Chronic viral hepatitis	Hepatitis B, Hepatitis C
Autoimmune	Autoimmune hepatitis
Metabolic	Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH)
Biliary	Primary biliary cholangitis (PBC), Primary sclerosing cholangitis (PSC), Autoimmune cholangiopathy
Cardiac	Cardiac cirrhosis (right heart failure, constrictive pericarditis)
Inherited metabolic	Hemochromatosis, Wilson's disease, Alpha-1 antitrypsin deficiency, Cystic fibrosis
Cryptogenic	No identifiable cause (~10%)

Alcohol-Associated Cirrhosis

70% of US adults drink alcohol; >7% consume >4-5 drinks five or more times/month
Produces fatty liver, alcoholic hepatitis, and cirrhosis
In alcohol-associated cirrhosis, nodules are usually <3 mm (micronodular); after cessation, mixed micro/macronodular pattern may develop
Alcohol also accelerates liver damage in patients with HCV, hemochromatosis, or MASH

Clinical Features

Symptoms and Signs

Clinical features reflect severity and reflect the two major consequences: portal hypertension and loss of hepatocellular function.

Hepatocellular failure:

Jaundice
Hypoalbuminemia (edema, ascites)
Coagulopathy (reduced clotting factor synthesis)
Spider angiomata, palmar erythema, gynecomastia, testicular atrophy
Muscle wasting/sarcopenia

Portal hypertension signs:

Splenomegaly
Caput medusae
Ascites
Esophageal/gastric varices

Key grading tool - Child-Pugh Score (used to assess severity): Incorporates bilirubin, albumin, PT/INR, ascites, and encephalopathy

MELD Score (Model for End-Stage Liver Disease): Used for transplant listing priority; incorporates creatinine, bilirubin, INR.

Major Complications

1. Portal Hypertension

Defined as HVPG >5 mmHg; clinically significant portal hypertension (CSPH) = HVPG ≥10 mmHg
Caused by: (1) increased intrahepatic resistance (cirrhosis, nodules, microthrombi) + (2) increased splanchnic blood flow (vasodilation)
Advanced stages: neurohumoral activation → sodium/water retention → hyperdynamic circulation

Causes categorized as:

Prehepatic: portal vein thrombosis, splenic vein thrombosis
Intrahepatic (>95% of cases): cirrhosis (sinusoidal); schistosomiasis, congenital hepatic fibrosis (presinusoidal); venoocclusive disease (postsinusoidal)
Posthepatic: Budd-Chiari syndrome, right heart failure

2. Gastroesophageal Variceal Hemorrhage

Life-threatening complication; occurs when HVPG >12 mmHg
Acute management: IV octreotide (somatostatin analogue, reduces splanchnic flow); endoscopic variceal ligation (EVL) is treatment of choice; balloon tamponade as bridge; TIPS for refractory bleeding
Primary prophylaxis: non-selective beta-blockers (propranolol, nadolol, or carvedilol) or EVL for large varices
Secondary prophylaxis: combination EVL + beta-blocker

3. Ascites

Most common complication of cirrhosis
Caused by: portal hypertension + renal sodium/water retention + hypoalbuminemia
Diagnosis: paracentesis; SAAG ≥1.1 g/dL confirms portal hypertension etiology
Treatment:
- First-line: sodium restriction (<2 g/day) + spironolactone (100-400 mg/day) ± furosemide (40-160 mg/day)
- Refractory ascites: large-volume paracentesis (LVP) with albumin infusion (6-8 g/L of fluid removed), TIPS
- Avoid NSAIDs, aminoglycosides

4. Spontaneous Bacterial Peritonitis (SBP)

Occurs in ~10-30% of hospitalized cirrhotics with ascites
Diagnosed by ascitic fluid PMN count ≥250 cells/mm³
Organisms: E. coli, Klebsiella, Streptococcus pneumoniae (gram-negatives most common)
Treatment: IV cefotaxime 2g q8h x 5 days; albumin IV (1.5 g/kg day 1, 1 g/kg day 3) to prevent hepatorenal syndrome
Prophylaxis: norfloxacin or ciprofloxacin for prior SBP (secondary), or if ascitic protein <1.5 g/dL + advanced liver disease (primary)

5. Hepatic Encephalopathy (HE)

Due to gut-derived neurotoxins (especially ammonia) bypassing liver via vascular shunting
Precipitants: GI bleeding, infection, hyponatremia, volume depletion, constipation, sedatives
Clinical features: confusion, personality change, asterixis ("liver flap"), altered consciousness; staging I-IV
Diagnosis: clinical; ammonia levels often elevated but correlate poorly with severity
Treatment:
- Identify and correct precipitants
- Lactulose (non-absorbable disaccharide) → colonic acidification → catharsis; goal: 2-3 soft stools/day
- Rifaximin 550 mg BID (poorly absorbed antibiotic) - adjunctive or for recurrent episodes; approved for maintenance
- Protein restriction is not recommended (worsens nutrition/sarcopenia)
- BCAA (branched-chain amino acids) supplementation may help in refractory cases

6. Hepatorenal Syndrome (HRS)

Functional renal failure in cirrhosis; no intrinsic renal pathology
Type 1 (HRS-AKI): rapid deterioration; creatinine >2.5 mg/dL within 2 weeks; poor prognosis
Type 2 (HRS-CKD): moderate, stable renal failure; mainly related to refractory ascites
Treatment: vasoconstrictors (terlipressin [first choice where available] or norepinephrine) + albumin; liver transplantation is definitive

7. Hepatocellular Carcinoma (HCC)

Occurs in ~1-5% of cirrhotics per year
Risk highest with: HBV, HCV, alcohol-associated cirrhosis, hemochromatosis, MASH
Surveillance: ultrasound ± AFP every 6 months

8. Hepatopulmonary Syndrome / Portopulmonary Hypertension

Rare pulmonary complications from advanced cirrhosis

Hematologic Abnormalities in Cirrhosis

Thrombocytopenia: splenomegaly + decreased thrombopoietin synthesis
Anemia: multifactorial (GI bleeding, folate deficiency, hemolysis, bone marrow suppression)
Coagulopathy: decreased synthesis of clotting factors (II, V, VII, IX, X) and protein C/S; however, INR overestimates bleeding risk as anti-coagulant factors also reduced

Bone Disease in Cirrhosis

Hepatic osteodystrophy: includes osteoporosis and osteomalacia
PBC and cholestatic disease carry highest risk
Calcium and vitamin D supplementation; bisphosphonates for established osteoporosis

Malnutrition in Cirrhosis

Nearly universal in advanced cirrhosis; associated with worse outcomes
Recommend: high-calorie, adequate protein diet (1.2-1.5 g/kg/day); small, frequent meals; late-evening snack to prevent fasting gluconeogenesis

Diagnosis

Laboratory Tests

Test	Finding
ALT/AST	Elevated (AST:ALT ratio >2 suggests alcohol)
Bilirubin	Elevated in decompensation
Albumin	Low (<3.5 g/dL)
PT/INR	Prolonged
Platelet count	Low (hypersplenism)
Sodium	Low (dilutional hyponatremia)
Creatinine	Elevated in HRS
AFP	Elevated in HCC

Imaging

Ultrasound: nodular liver surface, splenomegaly, ascites, portal vein diameter; first-line
Doppler US: portal vein flow direction, varices
CT/MRI: characterize liver architecture, detect HCC, assess vasculature
Elastography (FibroScan): non-invasive fibrosis assessment; measures liver stiffness in kPa

Liver Biopsy

Gold standard for diagnosis and staging
No longer routine; replaced in many situations by non-invasive markers (FIB-4, elastography)
Still used when: etiology unclear, non-invasive tests discordant, or before treatment decisions

Scoring Systems

Child-Pugh score (A/B/C): clinical assessment, prognosis
MELD score: predicts 3-month mortality; used for transplant allocation
MELD-Na: incorporates sodium; superior predictor; now used for UNOS/OPTN listing

Treatment

General Principles

Treat the underlying cause (etiologic therapy)
Prevent and manage complications
Assess for liver transplantation when decompensated

Etiology-Specific Treatment

Cause	Treatment
Alcohol-associated	Complete alcohol abstinence; nutritional support; corticosteroids for alcoholic hepatitis (Maddrey DF ≥32)
Chronic HCV	Direct-acting antivirals (sofosbuvir-velpatasvir or glecaprevir-pibrentasvir); >95% SVR; avoid protease inhibitors (glecaprevir, grazoprevir, voxilaprevir) in decompensated cirrhosis
Chronic HBV	Entecavir or tenofovir (TDF/TAF) - indefinite; suppress viral replication; reduces HCC risk
Autoimmune hepatitis	Prednisone ± azathioprine
PBC	Ursodeoxycholic acid (UDCA) 13-15 mg/kg/day; obeticholic acid for incomplete responders
PSC	UDCA (controversial); manage biliary strictures; high HCC/cholangiocarcinoma surveillance
Hemochromatosis	Phlebotomy
Wilson's disease	D-penicillamine or trientine; zinc acetate for maintenance
MASH	Weight loss (7-10%), exercise; GLP-1 agonists (semaglutide); resmetirom (approved 2024 for MASH with fibrosis)

Portal Hypertension Management

Non-selective beta-blockers (propranolol, nadolol, carvedilol): reduce portal pressure; primary and secondary prophylaxis for varices
TIPS (Transjugular Intrahepatic Portosystemic Shunt): reduces portal pressure; used for refractory ascites, refractory variceal bleeding; risk of encephalopathy

Liver Transplantation

Definitive treatment for end-stage liver disease
Indications: MELD ≥15, first decompensation, HCC within Milan criteria, HRS, recurrent SBP
Contraindications: active alcohol/substance use, extrahepatic malignancy, severe cardiopulmonary disease
5-year survival post-transplant: ~75-80%

Key References:

Harrison's Principles of Internal Medicine, 22nd Edition (2025) - Chapter 355: Cirrhosis and Its Complications
Harrison's 22e, Chapter 352: Chronic Hepatitis (HBV/HCV treatment)

This summary covers the full scope of chronic liver disease as presented in Harrison's 22nd Edition, integrating etiology, pathogenesis, clinical features, diagnostics, complications, and management.

This is a shared conversation. Sign in to Orris to start your own chat.